Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of CHF6001 DPI added to triple maintenance therapy in COPD with chronic bronchitis
MOH_2021-08-01_010177Phase 3Not yet recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tanimilast in chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Primary endpoint not reported. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
tanimilast
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)
Beyond the preview
Go deeper on MOH_2021-08-01_010177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-01_010177.